Early Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part in the study and sign a consent form agreeing to participate.
- People who are 18 years of age or older at the time they sign the consent form.
- People who have a pancreatic tumour that scans suggest can be fully removed by surgery and that appears to be a type called adenocarcinoma.
- People whose surgically removed pancreatic tumour has been confirmed by laboratory testing to be ductal pancreatic adenocarcinoma, and where the surgeon was able to remove all visible tumour tissue.
- People who are in generally good physical condition, able to carry out daily activities with little or no limitation (ECOG performance status 0 or 1 — confirm with trial site if unsure what this means).
- People who have not previously received chemotherapy, radiation therapy, or immunotherapy for pancreatic ductal adenocarcinoma.
- People whose doctors estimate they are likely to survive for more than 12 weeks.
Who may not be able to join:
- People who have previously received pre-surgery treatment, radiation therapy, or immune therapies (including anti-PD-1 medicines) for pancreatic ductal adenocarcinoma.
- People who have a known allergy or sensitivity to any of the study medicines: SJ-neo006, Camrelizumab, Gemcitabine, or Abraxane (nab-paclitaxel).
- People who have an active, uncontrolled infection (bacterial, viral, or fungal) that is not improving with appropriate treatment.
- People with a known current or past infection with Hepatitis B, Hepatitis C, or HIV, or people taking medicines that suppress the immune system or bone marrow in a way that may increase the risk of serious complications.
- People who are pregnant, breastfeeding, or planning to become pregnant during the study or within 90 days after the last dose of study treatment.
- People with serious heart conditions (such as severe heart failure, uncontrolled high blood pressure, significant heart rhythm problems, or abnormal heart test results), or who have had a stroke, mini-stroke, or seizure disorder.
- People who have a history of an autoimmune disease, such as lupus, rheumatoid arthritis, or inflammatory bowel disease.
- People whom the trial doctors consider may face increased risk or whose participation may affect the reliability of the trial results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xinbo Wang, MD, Jinling Hospital, China
Phone: 13505172912
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment Emergent Adverse Events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.